Roth's purported statement in The Fly On The Wall news break below (probably derived from Roth analyst Yale Jen) is most likely based on, among other things, a table of intralesional injection response rates shown at the conference that compared intralesional therapies IL-2, BCG, Allovectin-7, OncoVEX and PV-10.
Understanding the caveats of comparing trials, PV-10's response rates for injected lesions, non-injected lesions and non-injected systemic lesions exceeded those of both Vical's Allovectin-7 and Amgen/BioVex's OncoVex.
IL-2 and BCG response rates for injected lesions were higher than PV-10's; however, response rates for these two therapies were zero or smaller than PV-10's for non-injected lesions (zero for IL-2) and non-injected systemic lesions (zero for both).
No comments:
Post a Comment